PacBio Files 8-K on Operations and Financials

Ticker: PACB · Form: 8-K · Filed: 2025-01-14T00:00:00.000Z

Sentiment: neutral

Topics: operations, financials, sec-filing

Related Tickers: PACB

TL;DR

PacBio dropped an 8-K on Jan 14th covering ops and financials. No big news yet.

AI Summary

On January 14, 2025, Pacific Biosciences of California, Inc. (PacBio) filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along with other events and financial statements. No specific financial figures or new material events were detailed in the provided excerpt.

Why It Matters

This filing indicates PacBio is providing updates on its operational and financial status to the SEC, which is standard practice for publicly traded companies.

Risk Assessment

Risk Level: low — This is a routine 8-K filing for reporting operational and financial information, not indicating any immediate or significant new risks.

Key Players & Entities

FAQ

What specific financial results or operational updates are detailed in this 8-K filing?

The provided excerpt of the 8-K filing does not detail specific financial results or operational updates; it only indicates that the filing pertains to 'Results of Operations and Financial Condition'.

What is the primary purpose of this 8-K filing for Pacific Biosciences of California, Inc.?

The primary purpose of this 8-K filing is to report on the company's results of operations and financial condition, as well as other events and financial statements.

When was this 8-K filing submitted to the SEC?

This 8-K filing was submitted to the SEC on January 14, 2025.

What is the state of incorporation for Pacific Biosciences of California, Inc.?

Pacific Biosciences of California, Inc. is incorporated in Delaware.

What is the principal executive office address for Pacific Biosciences of California, Inc.?

The principal executive office address for Pacific Biosciences of California, Inc. is 1305 O'Brien Drive, Menlo Park, California 94025.

From the Filing

0001299130-25-000011.txt : 20250114 0001299130-25-000011.hdr.sgml : 20250114 20250114091053 ACCESSION NUMBER: 0001299130-25-000011 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250114 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250114 DATE AS OF CHANGE: 20250114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA, INC. CENTRAL INDEX KEY: 0001299130 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 161590339 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34899 FILM NUMBER: 25527892 BUSINESS ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-521-8000 MAIL ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA INC DATE OF NAME CHANGE: 20050829 FORMER COMPANY: FORMER CONFORMED NAME: NANOFLUIDICS INC DATE OF NAME CHANGE: 20040729 8-K 1 pacb-20250114.htm 8-K pacb-20250114 0001299130 false 0001299130 2025-01-14 2025-01-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 14, 2025 Pacific Biosciences of California, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34899 16-1590339 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 1305 O’Brien Drive Menlo Park , California 94025 (Address of principal executive offices) (Zip Code) ( 650 ) 521-8000 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share PACB The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o ITEM 2.02.    RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On January 14, 2025, Pacific Biosciences of California, Inc. (the “Company”) issued a press release providing a business update and announcing certain unaudited preliminary financial results as of and for the quarter and year ended December 31, 2024 (the “Press Release”). A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information in Item 2.02 of this Current Report on Form 8-K, including the sections of the Press Release incorporated by reference herein, sha

View on Read The Filing